Tag: HEA MTC PHA

RxPreferred Launches My-RxP: Cutting Costs for Brand, Specialty, GLP-1, and Fertility Medications by Up to 60%

NASHVILLE, Tenn., July 16, 2025 /PRNewswire/ -- RxPreferred, a leading transparent pharmacy benefit administrator, is proud to announce the launch of My-RxP, an innovative medication...

SIFI Announces Reimbursement Approval for AKANTIOR® in Spain

AKANTIOR® is anticipated to become available to Spanish patients on 1st August Spain is the first Country in the world to approve the pricing and...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm’s Series of...

SHENZHEN, China, July 4, 2025 /PRNewswire/ -- Recently, Kexing Biopharm made a remarkable appearance at CPHI & PMEC China 2025 and successfully organized the...

Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats

TORONTO, July 2, 2025 /PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept),...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsHEA MTC PHA

Tokyo Lifestyle Secures Strategic Franchise Partnership with FLUSH Co., Ltd. to Accelerate Expansion in Western Japan and Strengthen O2O Digital Capabilities

The Japanese Soy Milk Exchange Forms to Establish a New Soy Milk Category in the U.S.

Investeringsforeningen Multi Manager Invest – Offentliggørelse af prospekt

Tag: HEA MTC PHA

RxPreferred Launches My-RxP: Cutting Costs for Brand, Specialty, GLP-1, and Fertility Medications by Up to 60%

SIFI Announces Reimbursement Approval for AKANTIOR® in Spain

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm’s Series of...

Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats

BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize

Oncorena’s new issue of shares fully subscribed

Craft Telemedicine Launches to Redefine Specialty Care with Human-Centered Platform

Pharmacists Expand Clinical Footprint Across U.S. Hospitals

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us